Skip to main content
Figure 1 | Genetic Vaccines and Therapy

Figure 1

From: Combined vascular endothelial growth factor-A and fibroblast growth factor 4 gene transfer improves wound healing in diabetic mice

Figure 1

In vitro gene expression in AAV-transduced HeLa cells. (A) Schematic representation of expression cassettes in AAV vectors used for transduction: control vector encoding β-galactosidase - AAV-LacZ; VEGF-A overexpressing vector - AAV-VEGF-A; FGF4 (cap-dependent cistron) and GFP (IRES-dependent cistron) - AAV-FGF4-IRES-GFP; FGF4 (cap-dependent cistron) and VEGF-A (IRES-dependent cistron) - AAV-FGF4-IRES-VEGF-A. CMV ie enhancer - cytomegalovirus immediate-early enhancer. IRES - internal ribosome entry site. (B) β-galactosidase in situ staining of non-transduced or AAV-LacZ-transduced HeLa cells (arrows). (C) and (D) ELISA determining respectively, hVEGF-A and hFGF4 release into the cell culture media. Production of both hVEGF-A and hFGF4 proteins was significantly up-regulated after transduction with therapeutic vectors when compared to non-transduced (control) cells or cells transduced with AAV-LacZ vector. Representative data out of two independent experiments performed in duplicates. Values are means ± SD; *p < 0.05 vs control and AAV-LacZ. Scale bar = 0.1 mm.

Back to article page

Genetic Vaccines and Therapy

ISSN: 1479-0556